A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions
Non-infectious Intermediate Posterior- or Pan-uveitis
Interventions
DRUG

Adalimumab

Subcutaneous Injection

Trial Locations (7)

100034

Peking University First Hospital /ID# 243055, Beijing

100730

Beijing Tongren Hospital, CMU /ID# 243054, Beijing

200080

Shanghai General hospital /ID# 247252, Shanghai

300384

Tianjin Medical University Eye Hospital /ID# 243056, Tianjin

310009

The second affiliated hospital of Zhejiang University school of medicine /ID# 247251, Hangzhou

325612

Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253, Wenzhou

710000

Xi'an people's hospital/Xi'an fourth hospital /ID# 243371, Xi'an

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY